Analytical Data
-
Gene name
CCL17
- Application
-
Alternative Names
CCL17；SCYA17；TARC；C-C motif chemokine 17
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q92583
-
Expression Region
24-94aa
-
AA Sequence
ARGTNVGREC CLEYFKGAIP LRKLKTWYQT SEDCSRDAIV FVTVQGRAIC SDPNNKRVKN AVKYLQSLER S
-
Molecular Weight
8.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CCL17, also known as Thymus and Activation-Regulated Chemokine (TARC), is a member of the CC chemokine family that plays a crucial role in immune responses, particularly in the recruitment and activation of T cells and dendritic cells. Initially identified for its expression in thymic and activated tissues, CCL17 has garnered attention for its involvement in various pathological conditions, including allergic reactions, asthma, and certain inflammatory diseases. The protein is primarily produced by activated dendritic cells and macrophages, highlighting its role in orchestrating immune responses during infections and autoimmune disorders. Given its significant involvement in immune regulation and potential implications in therapeutic applications, the recombinant production of CCL17 has become a focus of research. By developing recombinant CCL17 proteins, researchers aim to better understand its functional mechanisms and interactions within the immune system. Furthermore, exploring CCL17's role in different disease models could pave the way for novel diagnostic and therapeutic strategies, especially in treating immune-mediated diseases. Overall, the study of CCL17 as a recombinant protein is vital for advancing our understanding of immune dynamics and improving therapeutic interventions in various diseases linked to immune dysfunction.
